Enorama Pharma (Sweden) Performance
| ERMA Stock | SEK 3.77 0.09 2.33% |
The firm shows a Beta (market volatility) of -0.21, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enorama Pharma are expected to decrease at a much lower rate. During the bear market, Enorama Pharma is likely to outperform the market. At this point, Enorama Pharma AB has a negative expected return of -0.37%. Please make sure to confirm Enorama Pharma's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Enorama Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | -1.8 M |
Enorama |
Enorama Pharma Relative Risk vs. Return Landscape
If you would invest 532.00 in Enorama Pharma AB on August 25, 2024 and sell it today you would lose (155.00) from holding Enorama Pharma AB or give up 29.14% of portfolio value over 90 days. Enorama Pharma AB is generating negative expected returns and assumes 5.4781% volatility on return distribution over the 90 days horizon. Simply put, 48% of stocks are less volatile than Enorama, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Enorama Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enorama Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enorama Pharma AB, and traders can use it to determine the average amount a Enorama Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0682
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ERMA |
Estimated Market Risk
| 5.48 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enorama Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enorama Pharma by adding Enorama Pharma to a well-diversified portfolio.
Enorama Pharma Fundamentals Growth
Enorama Stock prices reflect investors' perceptions of the future prospects and financial health of Enorama Pharma, and Enorama Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enorama Stock performance.
| Return On Equity | -32.88 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 42.1 M | |||
| Shares Outstanding | 10.69 M | |||
| Price To Book | 7.67 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 11.04 M | |||
| EBITDA | (25.56 M) | |||
| Cash And Equivalents | 2.01 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 1.7 M | |||
| Debt To Equity | 6.00 % | |||
| Book Value Per Share | (1.22) X | |||
| Cash Flow From Operations | (30.16 M) | |||
| Earnings Per Share | (4.92) X | |||
| Total Asset | 50.93 M | |||
About Enorama Pharma Performance
Assessing Enorama Pharma's fundamental ratios provides investors with valuable insights into Enorama Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Enorama Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about Enorama Pharma AB performance evaluation
Checking the ongoing alerts about Enorama Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enorama Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enorama Pharma AB generated a negative expected return over the last 90 days | |
| Enorama Pharma AB has high historical volatility and very poor performance | |
| Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M. | |
| Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 78.0% of Enorama Pharma shares are held by company insiders |
- Analyzing Enorama Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enorama Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Enorama Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enorama Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enorama Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enorama Pharma's stock. These opinions can provide insight into Enorama Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.